According to Cancer Research UK, there are around 6,600 new liver cancer cases in the UK every year, and around 5,830 people ...

Hepatocellular carcinoma is the most common form of primary liver cancer. It initiates in the body, beginning from the liver cells, or hepatocytes, usually developing in individuals with underlying ...

Hepatocellular carcinoma (HCC) is a significant global health concern ... Circulating tumor cells (CTCs), which are tumor ...

HCC incidence is rising due to MASLD, with lifestyle changes as the primary treatment. External validation is needed for the ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

The test has shown an 86% early-stage sensitivity and 88% specificity, outperforming traditional testing methods.

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...